Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Up 10.9% in January

Aspira Women’s Health Inc. (NASDAQ:AWH) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 439,200 shares, a growth of 10.9% from the January 15th total of 396,200 shares. Approximately 3.6% of the company’s stock are sold short. Based on an average trading volume of 97,900 shares, the short-interest ratio is presently 4.5 days.

Aspira Women’s Health Price Performance

Shares of NASDAQ AWH traded down $0.04 during trading on Friday, hitting $0.24. The stock had a trading volume of 907,741 shares, compared to its average volume of 106,812. Aspira Women’s Health has a 12 month low of $0.20 and a 12 month high of $5.00. The company has a market capitalization of $4.00 million, a PE ratio of -0.20 and a beta of 1.38. The firm has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.80.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 33.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $256,000 at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a report on Sunday, January 12th. They set a “hold” rating on the stock.

Aspira Women’s Health Company Profile

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.